DOACs vs Warfarin in Atrial Fibrillation Mitral Stenosis
Managing atrial fibrillation mitral stenosis presents a clinical challenge due to elevated stroke risks. A recent target trial emulation compared direct oral anticoagulants with warfarin in these high-risk patients.
Stroke Risk and DOACs in Atrial Fibrillation Mitral Stenosis
Researchers evaluated Asian patients diagnosed with both conditions over ten years. Surprisingly, direct oral anticoagulants increased the one-year risk of ischemic stroke compared to warfarin. However, treatment with DOACs resulted in a significant reduction in myocardial infarction cases. Overall, bleeding risks and all-cause mortality remained similar between both anticoagulant groups.
Clinical Implications for Asian Patients
Consequently, clinicians should exercise caution when prescribing DOACs off-label. Warfarin remains the standard recommendation for preventing thromboembolic events in this population. Therefore, close monitoring of anticoagulation therapy is essential for patient safety.
Frequently Asked Questions
Q1: Are DOACs safer than warfarin in patients with atrial fibrillation and mitral stenosis?
Study results show similar bleeding risks, but DOACs carried a higher one-year risk of ischemic stroke compared to warfarin.
Q2: Did DOACs offer any specific clinical benefit in the study?
Yes, patients receiving DOACs experienced a significantly lower risk of myocardial infarction compared to those taking warfarin.
References
- Yang Y et al. Real-World Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Mitral Stenosis : A Target Trial Emulation. Ann Intern Med. 2026 Aug 11. doi: 10.7326/ANNALS-25-04740. PMID: 42574730.
